Doxorubicin HEXAL

Quick links

Choose a section

Quick links to important sections

Advertisements

Doxorubicin HEXAL

Advertisements
Advertisements

Overview of Doxorubicin HEXAL

Quick Facts

Property Description
Active ingredient Doxorubicin hydrochloride
Form Sterile solution for injection/infusion
Pharmacological class Antineoplastic Agent, Anthracycline
General purpose To stop the growth of abnormal cells
Origin Semi-synthetic (derived from a bacterium)

What is Doxorubicin HEXAL and What Class Does it Belong To?

Doxorubicin HEXAL is a medicine, distributed by the company HEXAL, classified as an antineoplastic agent, the general term for drugs designed to fight tumors and abnormal cell growth. The medication's active compound is doxorubicin hydrochloride, which belongs to the potent anthracycline family of chemotherapy agents. This specific class is often subcategorized as an antitumor antibiotic, reflecting its historical semi-synthetic origin derived from compounds isolated from the Streptomyces peucetius bacterium. Doxorubicin is a core medicine used for systemic treatment protocols; its efficacy is clinically recognized by major oncological guidelines globally. Doxorubicin is chemically recognized as a hydroxy derivative of daunorubicin, a closely related anthracycline.


Composition, Form, and General Purpose

The medication is a single-ingredient product supplied by HEXAL as a sterile solution for injection/infusion, delivered into the body via the intravenous route (parenteral administration). This specific pharmaceutical form ensures precise and rapid systemic distribution, which is essential for its function against rapidly dividing cells. The drug's general therapeutic purpose is to achieve the slowing or stopping of cancer cell growth by utilizing its cytotoxic action. This function involves the drug acting as a potent Topoisomerase II Inhibitor, a mechanism that ultimately leads to the disruption of the DNA structure and prevents the abnormal cells from copying their genetic material and proliferating uncontrollably. This highly potent mechanism is typically employed in the management of solid tumors and hematological malignancies, as it has the ability to induce cell death in various cancer types.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine
Advertisements

What side effects are possible with Doxorubicin HEXAL?

Possible side effects and safety information

The safety profile for Doxorubicin HEXAL (Doxorubicin hydrochloride) is defined by regulatory bodies based on the frequency and the physiological systems affected by adverse reactions. This profile identifies key safety concerns and restrictions of use.

Serious Adverse Reactions

The primary serious adverse reactions documented in official regulatory labeling are related to the heart and blood system. The medication is associated with the risk of Cardiotoxicity and Congestive Heart Failure (CHF), which can be delayed and related to the total lifetime cumulative dose administered. Additionally, Severe Myelosuppression (a profound decrease in blood cell counts) is a dose-limiting, Very Common adverse effect that increases the risk of life-threatening infection. The risk of developing Secondary Acute Malignancies, such as leukemia, is also documented.

Frequency Classification and System-Organ Effects

Classification Examples of Documented Effects (SOC)
Very Common Myelosuppression (Blood and Lymphatic), Alopecia (Skin), Nausea, Vomiting (Gastrointestinal)
Common Delayed Cardiomyopathy (Cardiac), Phlebitis (General), Palmar-Plantar Erythrodysaesthesia Syndrome (Skin)
Uncommon/Rare Secondary Acute Myelogenous Leukemia, Anaphylactic Reactions

Myelosuppression typically reaches its lowest point (nadir) between 10 to 14 days after administration. Gastrointestinal effects, such as mucositis or stomatitis, are also classified as Very Common and can occur within 5 to 10 days.

Safety-Related Restrictions

Regulatory constraints note that use is contraindicated in certain pre-existing conditions, including severe myocardial insufficiency and severe persistent myelosuppression. Dosage adjustments are required for patients with hepatic impairment, and the medicine can cause infertility in both men and women. Special consideration is given to pediatric patients due to the increased risk of delayed cardiotoxicity.

Advertisements

Overdose and Emergency Response

Overdose of Doxorubicin HEXAL results in an exaggeration of the drug's known toxic effects, primarily affecting the hematological and cardiovascular systems. Officially documented manifestations include severe myelosuppression (leukopenia and thrombocytopenia) and severe mucositis/stomatitis.

The acute exposure carries the risk of life-threatening outcomes such as acute heart failure, irreversible myocardial damage, and profound myelosuppression potentially leading to severe infection or hemorrhage. The official profile for Doxorubicin establishes these systemic risks as the core concern in an overdose scenario.

When to Seek Urgent Medical Help

Regulatory labeling mandates that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately upon the recognition of severe or life-threatening symptoms.

Management procedures are strictly defined as symptomatic and supportive treatment, as no specific antidote is known to reverse the effects of the drug. Due to the potential for delayed and severe toxic effects, the official guidance requires intensive monitoring of cardiac function and hematological parameters, often involving prolonged hospital observation and specific supportive measures like blood product transfusions.

Advertisements

Therapeutic Uses of Doxorubicin HEXAL

What Doxorubicin HEXAL Treats: Main Uses and Benefits

A potent chemotherapy agent, Doxorubicin HEXAL (Doxorubicin hydrochloride) is applied in addressing a wide array of cancers. Generally, its primary goal is managing conditions characterized by increased physiological stress associated with malignancy. This medication is commonly used across therapeutic domains where additional symptomatic support is needed.

The drug is considered relevant for major solid tumors, including metastatic breast cancer, ovarian carcinoma, specific types of lung cancer, and sarcomas (soft tissue and bone). It is also applicable for managing hematological malignancies like leukemias (ALL, AML) and lymphomas (Hodgkin's and Non-Hodgkin's).

In specialized scenarios, such as adjuvant therapy for high-risk breast cancer or in the treatment of specific pediatric cancers like Wilms' Tumor and Neuroblastoma, it may assist with reducing the risk of recurrence after surgery, which supports general well-being during symptomatic phases.


Quick Fact: Therapeutic Use Context
Main Therapeutic Role Managing conditions involving widespread, uncontrolled cellular proliferation.
Symptom Context Relevant in contexts marked by heightened systemic burden caused by active disease.
General Benefit Provides support that helps ease the overall symptom load by contributing to tumor stabilization.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Doxorubicin HEXAL (Doxorubicin hydrochloride) is permitted for use in adult and pediatric patients for approved cancer indications. However, regulatory standards define strict criteria for non-eligibility and conditional use.

Absolute Contraindications (Must Not Use)

Use is prohibited in patients with known hypersensitivity to the drug or other anthracyclines. It is also contraindicated in patients with severe cardiac issues, including severe myocardial insufficiency, recent myocardial infarction, or severe arrhythmias. Patients who have already reached the maximum lifetime cumulative dose of anthracyclines must not use the medicine. Further contraindications include severe, persistent myelosuppression, a systemic infection, and severe hepatic impairment (e.g., bilirubin > 5 mg/dL).

Restricted and Conditional Use

Use is contraindicated during pregnancy and breastfeeding. Conditional use requires mandatory dose reductions for patients with moderate hepatic impairment or severe renal impairment (GFR < 10 mL/min). While pediatric and older adult patients are eligible, their maximum cumulative dosage is typically lower than the standard adult limit due to the risk of delayed cardiotoxicity.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Doxorubicin HEXAL is characterized by official restrictions on co-administration based on pharmacokinetic alteration, pharmacodynamic reinforcement, and chemical incompatibility.

Pharmacokinetic and Pharmacodynamic Interactions

Certain medicines are documented to alter the plasma exposure of Doxorubicin or contribute to additive toxicity. Concomitant use with inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) is associated with increased Doxorubicin plasma concentrations, while inducers of these same enzymes and transporters may decrease exposure. Exposure is also increased by Cyclosporine, and a significant decrease in clearance occurs if Paclitaxel is administered before Doxorubicin.

Pharmacodynamic interactions involve the additive risk of cardiotoxicity when combined with other cardiotoxic agents. Doxorubicin is also documented to increase the risk of specific organ toxicities with other cytotoxic drugs, such as potentiating 6-Mercaptopurine-induced hepatotoxicity.

Administration Restrictions

The regulatory label outlines several explicit restrictions to manage interaction risks:

  • Explicit Restrictions: The co-administration of Trastuzumab is restricted due to an increased risk of cardiac dysfunction. Dexrazoxane is restricted from use at the initiation of Doxorubicin regimens due to a decrease in tumor response rate.
  • Timing Rules: Doxorubicin must be administered prior to Paclitaxel if used concomitantly to maintain drug clearance.
  • Incompatibilities: Heparin and Fluorouracil must not be mixed with Doxorubicin HEXAL in the same infusion line due to chemical incompatibility and precipitation.
Advertisements

Mechanism of Action

How Doxorubicin HEXAL Works

Doxorubicin hydrochloride acts through a multi-pronged mechanism to disrupt the core processes of rapidly dividing cells, forcing them into self-destruction.

u1f9ec Genetic Damage and Topoisomerase II Poisoning

The drug's primary action is centered on the cell's genetic material. The molecule physically inserts itself into the DNA helix (intercalation) and acts as a Topoisomerase II ( Topo II) poison, trapping this enzyme in a state that creates irreversible DNA double-strand breaks ( DSBs). This simultaneous damage and blockage of repair mechanisms exceeds the capacity of the cell's defenses, leading to the activation of the DNA Damage Response pathway.

u1f4a5 Oxidative Stress and Apoptosis Induction

The widespread DNA damage is compounded by a second mechanism: the drug engages in redox cycling within the cell to generate toxic Reactive Oxygen Species ( ROS). When the damage becomes irreparable, these combined mechanisms force the cell to bypass survival signals and initiate apoptosis (programmed cell death). This cascade leads to the physiological outcome of reduced cellular proliferation.

u1f6e1️ Mechanistic Limitations and Resistance

The action of this mechanism can be physiologically constrained by the target cell's internal defenses. Mechanisms such as the overexpression of cellular pumps (P-glycoprotein) can actively transport the drug out of the cell, while enhanced antioxidant defenses can neutralize the ROS component, thereby limiting the drug's access to its DNA and Topo II targets.

Advertisements

Dosage and Administration Information

Doxorubicin HEXAL is a solution for injection/infusion and must be administered strictly according to established medical protocols. It is given by one of two recognized methods: Intravenous (IV) Infusion for systemic therapy or Intravesical Instillation for local treatment within the bladder. The medicine must never be given by the intramuscular or subcutaneous route.


Standard Dosing and Schedule

Systemic administration typically follows a cyclic regimen. For use as a single agent, the recommended starting dose is generally 60 mg/m^2 to 75 mg/m^2 of body surface area, administered intravenously, and repeated every 21 days. In combination therapy, the dose is often reduced, ranging from 40 mg/m^2 to 75 mg/m^2 every 21 to 28 days. The maximum recommended dose for systemic use is defined by a lifetime cumulative limit of 450 mg/m^2 to 550 mg/m^2.


Administration and Dose Adjustments

Preparation: The solution must be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection and must be protected from light until the infusion is complete. The IV dose is typically administered over a 3 to 10 minute period into a secure, free-flowing line.

Dose Modification: Dosage must be reduced in cases of impaired hepatic (liver) function, based on serum total bilirubin levels. For example, a 50% dose reduction may be required if bilirubin is 1.2-3.0 mg/dL. For older adults (aged 70 or above), a lower total cumulative dose of 450 mg/m^2 is often advised. The solution must not be mixed with other drugs, specifically heparin or fluorouracil, to prevent precipitation.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This information is provided for research context only and does not substitute for clinical evaluation. Consultation with a healthcare provider is essential before making treatment decisions.

This section outlines the research that has explored the potential for change in disease activity following the administration of doxorubicin.

Phase 3 Clinical Trials

Phase 3 trials examined the drug's role in combination with other agents and as a monotherapy. Studies explored changes in patient response rates and survival metrics across various tumor types.

  • Trial Data Overview:
    • Research has focused on breast, ovarian, and bladder cancers, among others. These trials typically compared doxorubicin-containing regimens against non-doxorubicin regimens or monotherapy.
    • Findings of studies indicated an association between doxorubicin administration and objective response rates (ORR) in several tumor types, consistent with its established use.

Evidence on Combination Use

Many studies have evaluated doxorubicin's administration alongside other chemotherapeutic agents to assess potential differences in outcomes compared to single-agent therapy or other combinations. Research frequently evaluates overall survival (OS) and progression-free survival (PFS) in these combination settings.

  • Key Findings:
    • Research evaluated whether the combined administration of doxorubicin and specific partner drugs was associated with a change in median OS within the study cohorts compared to monotherapy or alternative protocols.

Safety Profile and Research Needs

Research has consistently documented the adverse events profile associated with doxorubicin use, with a focus on its cardiac and hematological effects.

  • Tolerance Profile:
    • Research reports that adverse events are common and often dose-limiting. These typically involve myelosuppression (low blood counts) and dose-dependent cardiotoxicity. Monitoring of cardiac function is a standard practice informed by trial data.
    • Further research is needed to continue evaluating long-term toxicity management strategies and alternative dosing schedules to optimize the therapeutic index.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Doxorubicin HEXAL (FAQ)


Q: What is Doxorubicin HEXAL?

A: According to the official product information, Doxorubicin HEXAL is a medicine used to treat several types of cancer. It contains the active substance doxorubicin hydrochloride, which belongs to a group of medicines called cytostatics. Cytostatics work by interfering with cell growth, which is intended to reduce or eliminate cancer cells.

Q: How is Doxorubicin HEXAL given to patients?

A: Regulatory documents state that Doxorubicin HEXAL is always given as an intravenous infusion. This means the medicine is slowly administered directly into a vein, which is required to be done under the supervision of a physician or nurse experienced in chemotherapy.

Q: Can Doxorubicin HEXAL affect the heart?

A: Official product information indicates that Doxorubicin HEXAL can have an effect on the heart, especially at higher cumulative doses. Before and during treatment, doctors monitor heart function using tests like an electrocardiogram (ECG) or a MUGA scan. This is done to help detect any changes early, as official documentation notes that heart problems are a potential risk that may occur even months to years after stopping therapy.

Q: What happens if Doxorubicin HEXAL leaks out of the vein?

A: Studies and official information indicate that if the medicine leaks out of the vein, a condition called extravasation occurs. This can cause severe tissue damage at the injection site. If this occurs, regulatory guidelines mandate that the infusion be stopped immediately, and the healthcare professional may then need to move the injection to a different site.

Q: Does this medication cause hair loss?

A: Official product information states that hair loss is a common side effect of Doxorubicin HEXAL, known as alopecia. This effect is generally considered temporary, and hair growth is expected to return after treatment with the medicine is complete, according to regulatory information.

Advertisements

How should Doxorubicin HEXAL be stored and disposed of?

How to Store and Dispose of Doxorubicin HEXAL?

This medication requires specific, officially documented conditions for storage, handling, and disposal, as it is classified as a cytotoxic drug.

Requirement Type Official Regulatory Instruction
Mandatory Storage Conditions Refrigeration: Store the unopened vial at 2 C to 8 C (36 F to 46 F).
Prohibited Environment Do not freeze the product. If gelling occurs, allow it to warm to room temperature (15 C to 25 C) to return it to a liquid state.
Packaging & Protection Must be kept in the original outer carton to protect the solution from light.
In-Use Stability Once diluted, the solution has limited stability and must be used or properly discarded within the short time frame specified on the product label.
Child Protection Keep this medicine out of the sight and reach of children (a mandatory requirement).
Official Disposal Rules Cytotoxic Waste: All unused medication, expired product, and handling materials contaminated by the drug must be disposed of as hazardous waste according to all national and local regulations. Do not dispose of into wastewater or household trash.

The regulatory profile defines Doxorubicin HEXAL as a temperature- and light-sensitive cytotoxic drug that requires strict refrigeration and protection from light to maintain integrity. The medicine's hazardous classification mandates the use of specialized, controlled procedures for disposal, prohibiting its introduction into general waste streams.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doxorubicin HEXAL found in:

A-Z Index: